The abstract is read at the publisher; the summary is JClub's.
In the UK PROFILE trial of adults with newly diagnosed Crohn’s disease, top-down infliximab plus immunomodulator reduced 5-year Crohn’s-related abdominal surgery (6 vs 28).
- Why it matters: Although top-down anti-TNF improved 48-week outcomes, it was unclear whether starting treatment from diagnosis changes the long-term disease course.
- What they did: In a multicentre open-label randomized trial (40 UK hospitals), 389 participants were assigned to top-down or step-up strategies for 48 weeks, then followed up to 5 years using Kaplan–Meier and Cox models.
- The result: Surgery time was longer with top-down therapy (aHR 5·23, p=0·0008 for step-up vs top-down), and step-up also showed higher hospital admissions and faster progression to B2/B3 complications, without safety differences in serious infections or malignancies.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.